Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

54P - Development of a Prognostic Test for Breast Cancer Recurrence Using a Highly Efficient Molecular Profiling Platform


04 May 2022


Poster Display session


Paul Capewell


Annals of Oncology (2022) 33 (suppl_3): S123-S147. 10.1016/annonc/annonc888


P. Capewell1, J. Loane2, J. Robson1, H. VanSteenHouse1, D. Andersen1

Author affiliations

  • 1 BioClavis Ltd., Glasgow/GB
  • 2 Glasgow Royal Infirmary - NHS Greater Glasgow and Clyde, Glasgow/GB

Abstract 54P


Although the clinical utility of gene expression signatures for breast cancer is established, access to these prognostic tools is limited to specific patient profiles. The purpose of our study was to identify a set of gene transcripts associated with the likelihood of recurrence in HR+/HER2- breast cancer patients with the highly efficient TempO-Seq platform.


By targeted expression analysis of FFPE lysate samples from the NHS Greater Glasgow and Clyde biorepository a machine learning approach idendified a subset of transcripts that were prognostic for recurrence. A Cox proportional hazard model for 10-year recurrence was subsequently trained using these transcripts with HR+ samples that lacked overexpression of the HER2 receptor (n = 211) and tested in samples independent of training (n = 50).


The transcript panel analysed on the TempO-Seq platform provided prognostically significant information for breast cancer recurrence in our sample set (LRχ2 = 78.88, p < 0.001; HR = 2.41). These data indicated that patients could be grouped into low- and high-risk cohorts, with significantly different Kaplan-Meier curves for recurrence free survival (p < 0.001) and breast cancer-associated mortality (p = 0.013). Additionally, the prognostic information provided by the TempO-Seq-derived signature was independent of the UK-PREDICT tool (V2), suggesting complementary applications for the technology.


Our novel prognostic signature and testing method based on TempO-Seq profiling was developed using whole transcriptome analysis of a heterogeneously treated cohort in an adjuvant setting. This approach overcomes many of the technical limitations (e.g., does not require extraction) and cost barriers typically encountered with traditional molecular approaches such as qPCR, RNA-Seq, or molecular barcoding. The high throughput test can rapidly generate results from large numbers of patient samples for efficient turnaround times. More widely, the study demonstrates that TempO-Seq technology can be used for accelerated diagnostic panel development and clinical research. The described approach to estimate the risk of breast cancer recurrence can be further validated in prospectively designed trials.

Legal entity responsible for the study

BioClavis Ltd. Teaching and Learning Centre Queen Elizabeth University Hospital, 1345 Govan Rd, Glasgow G51 4TF, United Kingdom.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.